Last reviewed · How we verify
treatment of dvt and pe in adults
Approved treatments
Clinical guidelines
- FDA label — 2L
Dabigatran etexilate capsules are indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days. - FDA label — prophylactic
Dabigatran etexilate capsules are indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism in adult patients who have undergone hip replacement surgery. - FDA label — 2L
Dabigatran etexilate capsules are indicated for the treatment of venous thromboembolic events (VTE) in pediatric patients 8 to less than 18 years of age who have been treated with a parenteral anticoagulant for at least 5 days.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- treatment of dvt and pe in adults patent landscape — cliff calendar, originator estates, attackable patents
- treatment of dvt and pe in adults treatment landscape brief
- treatment of dvt and pe in adults treatment updates RSS
Frequently asked questions about treatment of dvt and pe in adults
What are the treatment guidelines for treatment of dvt and pe in adults?
FDA label publishes guidelines for treatment of dvt and pe in adults. 3 guideline references tracked.
Related
- Treatment landscape: treatment of dvt and pe in adults patent cliff · treatment of dvt and pe in adults CI report
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing